IN THE CLAIMS:

Claims 5 and 25-27 are amended herein. New claims 28 and 29 have been added. All claims currently pending and under consideration in the referenced application are shown below.

Listing of Claims:

1-4. (Canceled)

5. (Currently amended) A method of treating a patient for depression comprising administering to ~~said~~ the patient an effective amount of a compound having the following chemical structure:



wherein X^1 is either -Br, -Cl, -F, -I, $-CF_3$, alkyl, -OH, $-OCF_3$, -O-alkyl, or -O-acyl;
X^2 is either -Br, -Cl, -F, -I, $-CF_3$, alkyl, -OH, $-OCF_3$, -O-alkyl, or -O-acyl; ~~and~~
R^3 is either -H or $-CH_3$; and
~~or a~~ pharmaceutically acceptable salts thereof.

6. (Original) The method of claim 5, wherein X^1 is –F, -Cl, $-OCF_3$ or $-CF_3$ and X^2 is either 2-OCH_3, 2-CH_3, 3-F, 3-CF_3, or 4-CF_3.

7-20. (Canceled)

21. (Previously presented) The method of claim 5, wherein X^1 and X^2 are F, and R^3 is –H.

22. (Previously presented) The method of claim 21, wherein X^2 is at the 3-position.

23. (Previously presented) The method of claim 5, wherein X^1 and X^2 are F, and R^3 is $-CH_3$.

24. (Previously presented) The method of claim 23, wherein X^2 is at the 3-position.

25. (Currently amended) The method of claim 5, wherein ~~said~~ the compound is active at a serotonin reuptake site and at a N-methyl-D-aspartate (NMDA) receptor.

26. (Currently amended) The method of claim 5, wherein ~~said~~ the compound has an NMDA receptor IC_{50} of about 50 nM to about 1 μM.

27. (Currently amended) The method of claim 26, wherein ~~said~~ the compound has an NMDA receptor IC_{50} of about 100 nM to about 800 nM.

28. (New) The method of claim 5, wherein the compound has the chemical structure:



and pharmaceutically acceptable salts thereof.

29. (New) The method of claim 27, wherein the compound has the chemical structure:



and pharmaceutically acceptable salts thereof.